United States Patents
Mycoplasma (species in photo unknown) on the surface of a fibroblast, a collagen-forming cell
(Please note: Over 60 species of Mycoplasma exists, several unrelated to human diseases)
US Patent #5,242,820
Date of Patent: September 7, 1993
Addressing Mycoplasma fermentans incognitus
(Column 1, Lines 18-25)
"The present invention relates to a novel strain of mycoplasma isolated from a patient with AIDS. The mycoplasma is closely related to a species of human mycoplasma, M. fermentans. Upon characterization of this mycoplasma, it may be classified as a unique strain within the species M. fermentans incognitus. This novel strain of mycoplasma is referred to hereinafter as the incognitus strain or M. fermentans incognitus."
(Column 23, Lines 5-12)
"In addition to AIDS, M. fermentans has been implicated in a number of other Disease states including Chronic Fatigue Syndrome, Wegener's Disease, Sarcoidosis, respiratory distress syndrome, Kibuchi's disease, autoimmune diseases such as Collagen Vascular Disease and lupus, and chronic debilitating diseases such as Alzheimer's disease. M. fermentans incognitus may either be a causative agent of these diseases or a key co-factor in these diseases."
(Column 23, Lines 15-30)
"M. fermentans incognitus is known to be sensitive to a number of antibiotics, including doxycycline, quinolones such as ciprofloxacin, chloramphenicol and tetracycline. Therefore, effective treatment of any of the above implicated diseases should include administration of antibiotics to which M. fermentans incognitus is sensitive. When using the effective antibiotics as the active ingredients of pharmaceutical compositions, the pharmaceutical compositions may be administered by a variety of routes including oral, intravenous, aerosol and parenteral. The amount of active ingredient (antibiotic) necessary to treat an M. fermentans incognitus infection will depend on the body weight of the patient, but will usually be from about 0.001 to about 100 mg/kg of body weight, two to four times daily."
US Patent #5,534,413
Date of Patent: July 9, 1996
Addressing Mycoplasma penetrans
"Antigenically and genetically the mycoplasma is distinct from all other known mycoplasmas."
(Column 1, Lines 18-22)
"The present invention relates to a novel strain of mycoplasma isolated from a patient with AIDS. The mycoplasma does not appear to be related to any other species of human or animal mycoplasma. This novel mycoplasma is referred to hereinafter as M. penetrans."
(Column 2, Lines 62-67)
"In addition to the natural difficulty of morphological differentiation between the microorganisms and the protoplasm of infected cells the often poorly preserved formalin-fixed clinical materials present further limitations to any attempt to directly visualize mycoplasma organisms in the tissues."
(Column 3, Lines 21-26)
"On the other hand, mycoplasms are known to be extraordinary pathogens, capable of causing chronic debilitating diseases and producing a variety of clinical manifestations in animals and frequently suppressing host immune defense mechanisms."